BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Feb. 23, 2006
View Archived Issues
Axcan: Functional Dyspepsia Drug Fails In Phase III Trial
Axcan Pharma Inc.’s ITAX for functional dyspepsia fizzled in Phase III, but the company said it will continue to work with the compound in other indications such as diabetic gastropathy. (BioWorld Today)
Read More
PolyMedix Completes Reverse Merger, Closes $21.2M PIPE
Read More
Mad Cow Miscreant Necessary For Blood, Neural Self-Renewal
Read More
Cleveland BioLabs Files $14M IPO For Radiation Protection
Read More
CombinatoRx Halts Psoriasis Drug After Its Phase II Failure
Read More
Other News To Note
Read More
Clinic Roundup
Read More